Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wai Chun Bio-Technology Ltd. ( (HK:0660) ) has issued an update.
Wai Chun Bio-Technology Limited has announced a further delay in sending a shareholder circular related to a loan agreement with a borrower and certain non-compliance issues previously disclosed. The company now expects to dispatch the circular, which will provide additional details on the loan drawdowns, on or before 28 March 2026, citing the need for more time to prepare and finalise the required information.
The postponement extends the information timeline for shareholders seeking clarity on the financing arrangements and related compliance matters. While no change to the substance of the loan agreement or the non-compliance issues was indicated, the delay may prolong uncertainty for investors awaiting a fuller explanation of the transaction and its implications for the company’s governance and financial position.
More about Wai Chun Bio-Technology Ltd.
Wai Chun Bio-Technology Limited is a Hong Kong-listed company incorporated in the Cayman Islands and traded under stock code 660. The group operates in the bio-technology sector, with its activities overseen by chairman and chief executive officer Lam Ka Chun and a board comprising executive and independent non-executive directors.
Average Trading Volume: 147,145
Technical Sentiment Signal: Buy
Current Market Cap: HK$49.97M
See more insights into 0660 stock on TipRanks’ Stock Analysis page.